Novocure Reports Data Showing TTF Therapy in Combination With Chemotherapy Has the Potential to Increase Overall Survival for Patients With Advanced Non-Small Cell Lung Cancer

Data Presented Today at the 35th European Society for Medical Oncology Congress

MILAN, October 10, 2010 – Novocure reported today that patients with advanced non-small cell lung
cancer (NSCLC) achieved a significant increase in survival time when tumor
treating fields (TTF) therapy was added to chemotherapy, as compared to
previously reported outcomes for patients receiving chemotherapy alone. Dr.
Miklos [...]

Eisai’s Eribulin Mesylate Maintains Overall Survival Benefit in Patients With Metastatic Breast Cancer, Irrespective of Tumour Hormone Receptor Status

Results From the EMBRACE Study Reinforce Efficacy of Eribulin Across Several Patient Sub-Groups

MILAN, October 10, 2010 – Further results from the Phase III EMBRACE study presented today at the
European Society of Medical Oncology (ESMO) congress showed that Eisai's
eribulin mesylate maintained an overall survival (OS) benefit compared with
Treatment of Physician's Choice (TPC) in metastatic breast [...]